By Indication

Metabolic Disease Risk (T2D, Obesity, Dyslipidemia) Market Analysis

Cross-industry research covering Metabolic Disease Risk (T2D, Obesity, Dyslipidemia) across 1 market reportspanning Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics.

1 Reports

1 Industries

Reports Covering Metabolic Disease Risk (T2D, Obesity, Dyslipidemia)

Direct to Consumer Genetic Sequencing Market to Reach USD 4.7 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics·Market: USD 2.7 Billion (2025)·CAGR: 7.2%

The GLP-1 RA boom is generating secondary demand for metabolic genetic risk stratification, with several DTC operators launching 'GLP-1 readiness' panels that combine polygenic risk scores with response prediction markers.

13%

Market Share

9.3%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments